The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...
Chronic obstructive pulmonary disease (COPD) is a major cause of death among patients with renal cell carcinoma (RCC) in the United States, investigators reported at ASCO’s 2025 Genitourinary Cancers ...
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...
Sanofi has received FDA approval for Qfitlia, its innovative hemophilia therapy that represents the first antithrombin-lowering treatment for hemophilia A or B patients with or without inhibitors ...
Dupixent (dupilumab) is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available ...
A rapid test harnessing the power of AI is set to transform the diagnosis of a lung condition that affects 3 million people ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent for the treatment of COPD has been approved in more than 45 ... and interleukin-13 (IL13) pathways and the program focuses on a specific population of people with evidence of type-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback